DIASORIN S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 98.94 EUR | -.--% |
|
+0.65% | +6.11% |
| 30/05 | Funds move on Banco BPM, DiaSorin and Webuild. | AN |
| 30/05 | Futures bearish; focus on European data | AN |
| Sales 2024 * | 1.19B 1.29B 108B | Sales 2025 * | 1.28B 1.38B 115B | Capitalization | 5.27B 5.72B 477B |
|---|---|---|---|---|---|
| Net income 2024 * | 194M 211M 17.56B | Net income 2025 * | 214M 232M 19.37B | EV / Sales 2024 * | 5.05 x |
| Net Debt 2024 * | 724M 786M 65.58B | Net Debt 2025 * | 531M 577M 48.09B | EV / Sales 2025 * | 4.55 x |
| P/E ratio 2024 * |
30
x | P/E ratio 2025 * |
25.9
x | Employees | 3,209 |
| Yield 2024 * |
0.92% | Yield 2025 * |
1.07% | Free-Float | 37.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on DiaSorin S.p.A.
More press releases
| 1 week | +0.65% | ||
| 1 month | +7.40% | ||
| 3 months | +6.99% | ||
| 6 months | +14.28% | ||
| Current year | +6.11% |
1 week
97.82
101.35
1 month
91.28103.55
Current year
82.72103.55
1 year
81.24103.55
3 years
81.24208.80
5 years
81.24211.80
10 years
26.00211.80
| Managers | Title | Age | Since |
|---|---|---|---|
Carlo Rosa
CEO | Chief Executive Officer | 58 | 01/98/01 |
| Director of Finance/CFO | 53 | 01/11/01 | |
| Director/Board Member | 61 | 01/00/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 29/22/29 | |
Carlo Rosa
CEO | Chief Executive Officer | 58 | 01/98/01 |
| Director/Board Member | 61 | 01/00/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.76% | 14 M€ | -5.07% | ||
| 0.69% | 5 M€ | +12.55% | ||
| 0.17% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 98.94 | -1.70% | 208,590 |
| 30/24/30 | 100.6 | -0.10% | 104,859 |
| 29/24/29 | 100.8 | +2.16% | 170,281 |
| 28/24/28 | 98.62 | -0.20% | 132,094 |
| 27/24/27 | 98.82 | +0.53% | 45,494 |
Real-time Borsa Italiana, May 31, 2024 at 09:14 pm IST
More quotes
DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc.
At the end of 2023, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.
Calendar
06/06/2024
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
98.94
EUR
Average target price
100.1
EUR
Spread / Average Target
+1.15%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.11% | 5.72B | |
| -3.17% | 8.22B | |
| +31.98% | 5.67B | |
| -10.03% | 4.11B | |
| -59.94% | 2.68B | |
| +11.23% | 2.68B | |
| -5.14% | 2.37B | |
| +18.91% | 2.06B | |
| -7.56% | 1.8B | |
| +3.07% | 1.6B |
- Stock Market
- Equities
- DIA Stock
